Literature DB >> 17074284

Psychotropic medication use for behavioral symptoms of dementia.

Philip S Wang1, M Alan Brookhart, Soko Setoguchi, Amanda R Patrick, Sebastian Schneeweiss.   

Abstract

Behavioral disturbances associated with dementia are common and burdensome. Although no psychotropic medications are currently approved by the US Food and Drug Administration (FDA) to treat such behavioral symptoms, a variety of drug classes are commonly used for these purposes. Atypical antipsychotic medications may be somewhat effective and are generally considered the pharmacologic treatments of choice; however "black box" warnings have recently been added to their labels by the FDA, warning of significantly increased risks of short-term mortality. Older conventional antipsychotic medications may also be somewhat effective but appear to pose risks that can be at least as great as those of the newer atypical drugs. Although antidepressants, benzodiazepines, mood stabilizers, acetylcholinesterase inhibitors, and N-methyl-D-aspartate (NMDA) receptor antagonists may be considered, particularly in patients with specific types of symptomatology, even less is known about their effectiveness and safety. Also, although various psychotropic medications used for behavioral disturbances in dementia patients may be somewhat effective, they have been increasingly associated with important safety risks.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17074284     DOI: 10.1007/s11910-006-0051-6

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  50 in total

1.  Challenges to the use of nonpharmacologic interventions in nursing homes.

Authors:  Marisue Cody; Cornelia Beck; Bonnie L Svarstad
Journal:  Psychiatr Serv       Date:  2002-11       Impact factor: 3.084

2.  Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data.

Authors:  Henry A Nasrallah; Thantween White; Amelia T Nasrallah
Journal:  Am J Geriatr Psychiatry       Date:  2004 Jul-Aug       Impact factor: 4.105

3.  FDA warns antipsychotic drugs may be risky for elderly.

Authors:  Bridget M Kuehn
Journal:  JAMA       Date:  2005-05-25       Impact factor: 56.272

4.  Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.

Authors:  Rosa Liperoti; Giovanni Gambassi; Kate L Lapane; Claire Chiang; Claudio Pedone; Vincent Mor; Roberto Bernabei
Journal:  Arch Intern Med       Date:  2005-03-28

5.  Behavioral and neuropsychiatric outcomes in Alzheimer's disease.

Authors:  Jeffrey L Cummings
Journal:  CNS Spectr       Date:  2005-11       Impact factor: 3.790

Review 6.  Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

Authors:  A H Glassman; J T Bigger
Journal:  Am J Psychiatry       Date:  2001-11       Impact factor: 18.112

Review 7.  Atypical antipsychotics in older adults.

Authors:  Y C Chan; S F Pariser; G Neufeld
Journal:  Pharmacotherapy       Date:  1999-07       Impact factor: 4.705

Review 8.  Assessment and treatment of nursing home residents with depression or behavioral symptoms associated with dementia: a review of the literature.

Authors:  Mark Snowden; Kersten Sato; Peter Roy-Byrne
Journal:  J Am Geriatr Soc       Date:  2003-09       Impact factor: 5.562

9.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

10.  A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

Authors:  Henry Brodaty; David Ames; John Snowdon; Michael Woodward; Jeff Kirwan; Roger Clarnette; Emma Lee; Ben Lyons; Fred Grossman
Journal:  J Clin Psychiatry       Date:  2003-02       Impact factor: 4.384

View more
  7 in total

1.  Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes.

Authors:  Krista F Huybrechts; Kenneth J Rothman; Rebecca A Silliman; M Alan Brookhart; Sebastian Schneeweiss
Journal:  CMAJ       Date:  2011-03-28       Impact factor: 8.262

Review 2.  Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.

Authors:  Gregory A Jicha
Journal:  J Mol Neurosci       Date:  2011-06-07       Impact factor: 3.444

3.  Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Neurodegener Dis Manag       Date:  2011-04

4.  Comparative safety of antipsychotic medications in nursing home residents.

Authors:  Krista F Huybrechts; Sebastian Schneeweiss; Tobias Gerhard; Mark Olfson; Jerry Avorn; Raisa Levin; Judith A Lucas; Stephen Crystal
Journal:  J Am Geriatr Soc       Date:  2012-02-13       Impact factor: 5.562

5.  Assessing residual confounding of the association between antipsychotic medications and risk of death using survey data.

Authors:  Sebastian Schneeweiss; Soko Setoguchi; M Alan Brookhart; Liljana Kaci; Philip S Wang
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

6.  Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities.

Authors:  Linda Simoni-Wastila; Priscilla T Ryder; Jingjing Qian; Ilene H Zuckerman; Thomas Shaffer; Lirong Zhao
Journal:  Am J Geriatr Psychiatry       Date:  2009-05       Impact factor: 4.105

7.  Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.

Authors:  K F Huybrechts; T Gerhard; S Crystal; M Olfson; J Avorn; R Levin; J A Lucas; S Schneeweiss
Journal:  BMJ       Date:  2012-02-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.